Assignee
SPARK THERAPEUTICS INC
US·7 granted patents·33 pending applications·0 citations·filing 2016–2025
Top patents by PatentIndex Score
40 records- 0177US2025305024A1Relative potency assay for viral vector encoding isomerohydrolasesSPARK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0275US2025171521A1CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0372US2022387560A1Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0466US2024101972A1Methods of regulating adeno-associated virus productionSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0566US2025073353A1Factor viii (fviii) gene therapy methodsSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0666US2025101396A1Codon-optimized acid alpha-glucosidase expression cassettes and methods of using sameSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0762US2019038724A1Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 0861US11168124B2CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disordersSPARK THERAPEUTICS INC·Filed 2017·Granted Nov 9, 2021·0 cites·41 claims
- 0961US2026078097A1Piperazine compoundsSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1059US2024271159A1Aav vector column purification methodsSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1158US12359239B2Relative potency assay for viral vector encoding isomerohydrolasesSPARK THERAPEUTICS INC·Filed 2017·Granted Jul 15, 2025·0 cites·50 claims
- 1258US2024350667A1Method of Enhancing Gene Therapy by Targeting cGAS-STING PathwaySPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1358US2025302990A1Enhancing non-viral dna delivery and expressionSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1457US2025228928A1Immune enhancement and infectious disease treatmentSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1556US12290574B2Optimized promoter sequences, intron-free expression constructs and methods of useSPARK THERAPEUTICS INC·Filed 2019·Granted May 6, 2025·0 cites·35 claims
- 1656US12084693B2Codon-optimized acid alpha-glucosidase expression cassettes and methods of using sameSPARK THERAPEUTICS INC·Filed 2019·Granted Sep 10, 2024·0 cites·40 claims
- 1756US2025221932A1Immune enhancement of cancer treatmentSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1855US2024074986A1Methods of Enhancing Non-Viral Gene TherapySPARK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1955US2016346359A1Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2050US2023040275A1Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disordersSPARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2150US2021371877A1Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of useSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2250US2024110201A1Compositions and Methods for Treating Hereditary AngioedemaSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2348US2022025396A1Plasmid free aav vector producing cell linesSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2447US2022184188A1Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2SPARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2546US2025387510A1Adeno-associated virus formulationsSPARK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2646US2021079422A1Aav vector column purification methodsSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2746US2020164008A1Apheresis methods and usesSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2846US2024301380A1Compositions and Methods for Treating Fabry DiseaseSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2945US2018312571A1CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3045US2022011308A1In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodiesSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3145US2020237930A1Factor viii (fviii) gene therapy methodsSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3243US12404526B2Enhancing agents for improved cell transfection and/or rAAV vector productionSPARK THERAPEUTICS INC·Filed 2018·Granted Sep 2, 2025·0 cites·37 claims
- 3343US10633689B2Rab Escort Protein potency assaySPARK THERAPEUTICS INC·Filed 2017·Granted Apr 28, 2020·0 cites·32 claims
- 3443US2019192693A1Methods and vectors for treating cns disordersSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3542US11702639B2Column-based fully scalable rAAV manufacturing processSPARK THERAPEUTICS INC·Filed 2017·Granted Jul 18, 2023·0 cites·47 claims
- 3642US2019284576A1SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBYSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3741US2019292561A1Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical useSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3839US2021363192A1Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using sameSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3938US2019078099A1Cell line for recombinant protein and/or viral vector productionSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4032US2023241247A1Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulinsSPARK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →